» Authors » Jason D Robarge

Jason D Robarge

Explore the profile of Jason D Robarge including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 9
Citations 189
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Robarge J, Budge K, Her L, Patterson A, Brown-Augsburger P
Antibodies (Basel) . 2025 Jan; 14(1. PMID: 39846610
Background: The prediction of human clearance (CL) and subcutaneous (SC) bioavailability is a critical aspect of monoclonal antibody (mAb) selection for clinical development. While monkeys are a well-accepted model for...
2.
Gufford B, Robarge J, Eadon M, Gao H, Lin H, Liu Y, et al.
Pharmacol Res Perspect . 2018 Apr; 6(2):e00386. PMID: 29610665
Rifampin is a pleiotropic inducer of multiple drug metabolizing enzymes and transporters. This work utilized a global approach to evaluate rifampin effects on conjugating enzyme gene expression with relevance to...
3.
Robarge J, Desta Z, Nguyen A, Li L, Hertz D, Rae J, et al.
Breast Cancer Res Treat . 2016 Dec; 161(3):453-461. PMID: 27943008
Purpose: Inter-individual differences in estrogen concentrations during treatment with aromatase inhibitors (AIs) may contribute to therapeutic response and toxicity. The aim of this study was to determine plasma concentrations of...
4.
Robarge J, Metzger I, Lu J, Thong N, Skaar T, Desta Z, et al.
Antimicrob Agents Chemother . 2016 Nov; 61(1). PMID: 27799204
Efavirenz pharmacokinetics is characterized by large between-subject variability, which determines both therapeutic response and adverse effects. Some of the variability in efavirenz pharmacokinetics has been attributed to genetic variability in...
5.
Abdelhady A, Shugg T, Thong N, Lu J, Kreutz Y, Jaynes H, et al.
J Cardiovasc Electrophysiol . 2016 Jun; 27(10):1206-1213. PMID: 27333947
Background: Efavirenz (EFV) has been associated with torsade de pointes despite marginal QT interval lengthening. Since EFV is metabolized by the cytochrome P450 (CYP) 2B6 enzyme, we hypothesized that EFV...
6.
Robarge J, Duarte D, Shariati B, Wang R, Flockhart D, Vasko M
Exp Neurol . 2016 Apr; 281:53-65. PMID: 27072527
Although aromatase inhibitors (AIs) are commonly used therapies for breast cancer, their use is limited because they produce arthralgia in a large number of patients. To determine whether AIs produce...
7.
Borges S, Desta Z, Jin Y, Faouzi A, Robarge J, Philips S, et al.
J Clin Pharmacol . 2010 Jan; 50(4):450-8. PMID: 20081063
Accurate assessment of CYP2D6 phenotypes from genotype is inadequate in patients taking CYP2D6 substrate together with CYP2D6 inhibitors. A novel CYP2D6 scoring system is proposed that incorporates the impact of...
8.
Jin Y, Hayes D, Li L, Robarge J, Skaar T, Philips S, et al.
J Clin Oncol . 2008 Nov; 26(36):5849-54. PMID: 19018086
Purpose: Hot flashes are common and frequently lead to drug discontinuation among women prescribed tamoxifen. We determined whether genetic polymorphisms in estrogen receptors (ESRs) alpha and beta (ESR1 and ESR2,...
9.
Schneider B, Radovich M, Flockhart D, Carpenter J, Li L, Robarge J, et al.
Breast Cancer Res Treat . 2008 Sep; 116(3):543-9. PMID: 18785001
Purpose: Hot flashes are a common symptom and an important cause of decreased quality of life in women with breast cancer. Hot flashes involve vasodilatation and flushing, however, their complex...
10.
Schneider B, Radovich M, Sledge G, Robarge J, Li L, Storniolo A, et al.
Breast Cancer Res Treat . 2007 Sep; 111(1):157-63. PMID: 17891484
Background: Few studies have systematically explored a pathway approach: to test the association of multiple polymorphisms from multiple genes important to angiogenesis simultaneously with risk of breast cancer. We report...